2. Search Result
Search Result
Results for "

diet-induced obese

" in MedChemExpress (MCE) Product Catalog:

104

Inhibitors & Agonists

1

Biochemical Assay Reagents

18

Peptides

15

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14393
    Emodin
    Maximum Cited Publications
    39 Publications Verification

    Frangula emodin

    		 SARS-CoV Casein Kinase Autophagy 11β-HSD Cancer
    Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .
    Emodin
  • HY-130208
    Thiodigalactoside
    5 Publications Verification

    TDG

    		 Galectin Metabolic Disease Inflammation/Immunology Cancer
    Thiodigalactoside (TDG) is an orally active and potent galectin (GAL) inhibitor with Kd values of 24 μM, 49 μM for GAL1 and GAL3, respectively . Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity. Thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats .
    Thiodigalactoside
  • HY-P10745
    Petrelintide

    ZP8396

    		 Amylin Receptor Metabolic Disease
    Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research .
    Petrelintide
  • HY-N8518
    Malabaricone C
    3 Publications Verification

    		 Phospholipase p38 MAPK Apoptosis NF-κB Metabolic Disease Inflammation/Immunology Cancer
    Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC50 values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells .
    Malabaricone C
  • HY-124758
    SH-BC-893

    		Mitochondrial Metabolism Metabolic Disease Cancer
    SH-BC-893 is an orally active anti-neoplastic sphingolipid analog. SH-BC-893 also protects from ceramide-induced mitochondrial dysfunction and corrects diet-induced obesity. SH-BC-893 can be used for the research of cancer and obesity .
    SH-BC-893
  • HY-P10745A
    Petrelintide acetate

    ZP8396 acetate

    		 Amylin Receptor Metabolic Disease
    Perelintide (ZP8396) acetate is a dual amylin and calcitonin receptor agonist (DACRA). Perelintide acetate elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Perelintide acetate can be utilized in diabetes research .
    Petrelintide acetate
  • HY-P10746
    EB1002

    		Neurokinin Receptor Metabolic Disease
    EB1002 is a highly selective, long-acting NK2R agonist. EB1002 exerts central appetite suppression, increases peripheral energy expenditure and enhances insulin sensitivity, which effectively reduces body weight, improves glucose and lipid metabolism, with favorable safety profiles. EB1002 can be used for research on diseases such as obesity and type 2 diabetes .
    EB1002
  • HY-W587486
    N-Acetyltaurine

    		Endogenous Metabolite Bacterial Metabolic Disease
    N‑acetyltaurine is an orally active endogenous sulfonate that is synthesized from taurine and acetate in the renal cortex. N‑acetyltaurine supports bacterial growth as a sole fixed nitrogen or carbon source. N‑acetyltaurine buffers acetyl moieties of mitochondrial acetyl‑CoA in skeletal muscle. N‑acetyltaurine reduces food intake and body weight in obese and lean wild‑type mice in a GFRAL‑dependent manner. N‑acetyltaurine can be used for the research of diet‑induced obesity, hyperacetatemia and diabetes .
    N-Acetyltaurine
  • HY-156438
    Ruvonoflast

    NT-0796

    		 NOD-like Receptor (NLR) Interleukin Related Neurological Disease
    Ruvonoflast (NT-0796) is an orally active, selective and CNS-penetrant NLRP3 inflammasome inhibitor. Ruvonoflast inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM. Ruvonoflast is an isopropyl ester that undergoes intracellular conversion to Ruvonoflast, the carboxylic acid active species. Ruvonoflast reverses high fat diet-induced obesity, systemic inflammation and astrogliosis in the diet-induced obesity mouse model. Ruvonoflast is promising for research of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis .
    Ruvonoflast
  • HY-P11245A
    NN1213 acetate

    		Amylin Receptor Metabolic Disease
    NN1213 acetate, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 acetate significantly reduces food intake and fat mass. NN1213 acetate can reduce body weightin diet-induced obese rats. NN1213 acetate can be used for the research of obesity .
    NN1213 acetate
  • HY-14229
    TGR5 Receptor Agonist
    3 Publications Verification

    CCDC

    		 G protein-coupled Bile Acid Receptor 1 Calcium Channel Metabolic Disease
    TGR5 Receptor Agonist (CCDC), a potent Takeda G protein-coupled receptor 5 (TGR5; GPCR19) agonist, shows improved potency in the U2-OS cells and melanophore cells with pEC50s of 6.8 and 7.5, respectively. TGR5 Receptor Agonist can induce peripheral and central hypersensitivity to bladder distension in mice, and increase intracellular Ca 2+ concentration. TGR5 Receptor Agonist can also reduces food intake and improves insulin responsiveness, in diet-induced obese mice. TGR5 Receptor Agonist can be used to research diabetes, bladder hypersensitivity and anti-obesity .
    TGR5 Receptor Agonist
  • HY-177475
    LysoPC(20:4)

    1-Arachidonoyl-sn-glycero-3-phosphocholine

    		 Endogenous Metabolite Metabolic Disease Cancer
    LysoPC 20:4 (20:4) (1-Arachidonoyl-sn-glycero-3-phosphocholine) is a serum metabolite. LysoPC 20:4 (20:4) decreases in tumor-bearing mice, but the reduction is not significant. LysoPC (20:4) can be used in cancer and obesity-related research .
    LysoPC(20:4)
  • HY-N0468
    Rebaudioside D
    1 Publications Verification

    		 FXR Acetyl-CoA Carboxylase Metabolic Disease
    Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D
  • HY-151500
    JBSNF-000028 free base

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 free base
  • HY-12443
    PF-5006739

    		Casein Kinase Neurological Disease
    PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC50s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner . PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity .
    PF-5006739
  • HY-124529
    Lunularin

    		11β-HSD Endogenous Metabolite Metabolic Disease Inflammation/Immunology Cancer
    Lunularin is an inhibitor of 11β-hydroxysteroid dehydrogenase 1, with an IC50 of 45.44 μM and a Ki of 35.8 μM against human 11β-HSD1, and an IC50 of 17.39 μM and a Ki of 10.31 μM against rat 11β-HSD1. Lunularin upregulates the transcription levels of Sirt1 and Hmox1 genes in the liver. Lunularin reduces food intake and body weight gain, and decreases blood glucose levels in mice fed a high-fat diet. Lunularin inhibits LPS-induced TLR4-mediated NF-κB pathway activation and nitric oxide production. Lunularin inhibits the proliferation and colony formation of renal cancer and colon cancer cells, and exhibits cancer cell-specific cytotoxicity. Lunularin binds to the steroid-binding site of human 11β-HSD1 and the steroid/NADPH-binding region of rat 11β-HSD1, but does not inhibit 11β-HSD2 or mouse 11β-HSD1. Lunularin can be used in research related to diet-induced obesity, renal cancer, colorectal cancer, inflammatory diseases and metabolic syndrome .
    Lunularin
  • HY-160912
    ELOVL6-IN-5

    		ELOVL Metabolic Disease
    ELOVL6-IN-5 is an orally active and selective elongase enzyme of long-chain fatty acid family 6 (ELOVL6) inhibitor with IC50 values of 85 nM and 38 nM for human and mouse ELOVL6, respectively. ELOVL6-IN-5 shows >60-fold selectivity over other ELOVL family enzymes (ELOVL1, 2, 3, 5) and no effect on other lipid synthesis enzymes like ACC1, ACC2. ELOVL6-IN-5 reduces hepatic fatty acid composition ratio of C18 to C16 in diet-induced obesity (DIO) and KKAy mice. ELOVL6 inhibition by ELOVL6-IN-5 does not improve insulin resistance. ELOVL6-IN-5 can be used for the research of metabolic disease .
    ELOVL6-IN-5
  • HY-13467
    AM-1638
    3 Publications Verification

    		 Free Fatty Acid Receptor Metabolic Disease
    AM-1638 is an orally active full agonist of GPR40 (EC50: 0.16 μM). AM-1638 increases the expression of antioxidant molecules (HO-1 and NQO-1). AM1638 blocks Palmitate (HY-N0830)-mediated superoxide production and ER stress. AM-1638 has antidiabetic activity and improves glycemic control in BDF mice with diet-induced obesity (DIO). AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%) .
    AM-1638
  • HY-117427
    D5D-IN-326
    2 Publications Verification

    		 Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .
    D5D-IN-326
  • HY-121744
    PS10
    5+ Cited Publications

    		 PDHK Inflammation/Immunology
    PS10 is a novel, potent and ATP-competitive pan-PDK inhibitor, inhibits all PDK isoforms with IC50 of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (Kd= 239 nM) than for Hsp90 (Kd= 47 μM) . PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy .PDK: pyruvate dehydrogenase kinase
    PS10
  • HY-107734
    L 152804

    		Neuropeptide Y Receptor Metabolic Disease Endocrinology
    L 152804 is an orally active and selective neuropeptide Y Y5 receptor (NPY5-R) antagonist, with a Ki of 26 nM for hY5. L 152804 causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure .
    L 152804
  • HY-14342
    MK-5046
    2 Publications Verification

    		 Bombesin Receptor Metabolic Disease
    MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
    MK-5046
  • HY-14423
    Velneperit
    1 Publications Verification

    S2367

    		 Neuropeptide Y Receptor Neurological Disease Metabolic Disease
    Velneperit (S-2367) is an orally active neuropeptide Y (NPY) Y5 receptor antagonist that can penetrate the blood-brain barrier. Velneperit inhibits the appetite-stimulating and metabolism-inhibiting effects mediated by NPY. Velneperit selectively improves diet-induced obesity in mice. Velneperit enhances the expression of fear acutely by removing the inhibition of CeA Drd2 neurons. Velneperit can be used for the study of obesity .
    Velneperit
  • HY-P11245
    NN1213

    		Amylin Receptor Metabolic Disease
    NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity .
    NN1213
  • HY-114557
    NSC 90469

    3,5-Diiodo-L-thyronine

    		 JNK NF-κB Sirtuin PGC-1α COX TGF-β Receptor Collagen Metabolic Disease Inflammation/Immunology Endocrinology
    NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
    NSC 90469
  • HY-177704
    ACSL5-IN-1

    		ACSL Family Drug Derivative Metabolic Disease Cancer
    ACSL5-IN-1 (Compound A) is an ACSL5 inhibitor with body weight-reducing activity. ACSL5-IN-1 inhibits ACSL5, an enzyme linked to fatty acid metabolism. ACSL5-IN-1 reduces body weight in diet-induced obesity mice. ACSL5-IN-1 can be used for the research of obesity, metabolic dysfunction-associated steatohepatitis, metabolic syndrome, non-alcoholic fatty liver disease, type 2 diabetes, acute myeloid leukemia, colorectal cancer, and breast cancer .
    ACSL5-IN-1
  • HY-130687A
    Psicose

    DL-Psicose

    		 PI3K mTOR Akt IGF-1R TGF-beta/Smad Mitochondrial Metabolism Neurological Disease Metabolic Disease
    Psicose (DL-Psicose) is an orally effective sugar substitute. Psicose activates the PI3K/Akt/mTOR pathway to promote muscle synthesis. Psicose upregulates IGF-1 and downregulates Myostatin. Psicose normalizes mitochondrial dysfunction by increasing G6P activity. Psicose enhances the activity of antioxidant enzymes and reduces oxidative stress markers. Psicose increases muscle mass, grip strength and muscle weight in aged mice and diet-induced obese mice. Psicose improves obesity and type 2 diabetes. Psicose can be used in the research of age-related sarcopenia .
    Psicose
  • HY-N0046
    Notoginsenoside Fe

    Notoginseng triterpenes; Ginsenoside Mb

    		 Apoptosis Src Neurological Disease Metabolic Disease Cancer
    Notoginsenoside Fe (Notoginseng triterpenes; Ginsenoside Mb) is a saponin with anti-obesity and anti-neuroblastoma activities. Notoginsenoside Fe can be isolated from leaves of Panax notoginseng. Notoginsenoside Fe specifically activates paraventricular nucleus neurons in the hypothalamus, effectively reducing body weight, improving fasting blood glucose and protecting liver function by decreasing food intake, increasing resting metabolic rate and enhancing energy expenditure. Notoginsenoside Fe also inhibits the c-Src signaling pathway, blocks the proliferation and viability of human neuroblastoma cells, while improving mitochondrial dysfunction and alleviating apoptosis. Notoginsenoside Fe can be used in studies related to diet-induced obesity and neuroblastoma .
    Notoginsenoside Fe
  • HY-W009417
    Cedryl acetate

    		Environmental Pollutants Glycosidase Metabolic Disease
    Cedryl acetate is an orally active α-glucosidase inhibitor with an IC50 of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome .
    Cedryl acetate
  • HY-124314
    LEI-106

    		MAGL DAGL Metabolic Disease
    LEI-106 is a dual ABHD6 and DAGL-α inhibitor, with a Ki of 0.8 μM for ABHD6, and an IC50 of 18 nM and a Ki of 0.7 μM for DAGL-α. LEI-106 blocks the synthesis of 2-arachidonoylglycerol, reduces the level of endothelial cell-derived 2-arachidonoylglycerol, without altering the levels of cannabinoids and diacylglycerol. LEI-106 is applicable to research related to diet-induced obesity and metabolic syndrome .
    LEI-106
  • HY-151500B
    JBSNF-000028 hydrochloride

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 hydrochloride is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 hydrochloride can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 hydrochloride exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 hydrochloride can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 hydrochloride
  • HY-P10769
    MOTS-c (mouse)
    2 Publications Verification

    		 AMPK Apoptosis Metabolic Disease
    MOTS-c (mouse) is a mitochondrial-derived polypeptide that can be used to regulates pancreatic cell function. MOTS-c (mouse) reduces insulin secretion and expression in INS-1E cells, and enhances glucagon secretion and expression in αTC-1 cells. MOTS-c (mouse) decreases the apoptosis in INS-1E and αTC-1. MOTS-c (mouse) counteracts diet-induced obesity and insulin resistance through AMPK activation .
    MOTS-c (mouse)
  • HY-P10032
    NN1177

    NNC9204-1177

    		 GCGR GLP Receptor Cytochrome P450 Metabolic Disease
    NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice .
    NN1177
  • HY-135115
    Oleuropein Aglycone

    3,4-DHPEA-EA

    		 α-synuclein HDAC Adrenergic Receptor Inflammation/Immunology
    Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.
    Oleuropein Aglycone
  • HY-161297A
    NT-0249 free base

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NT-0249 free base is an orally active NLRP3 inhibitor. NT-0249 has anti-inflammatory activity .
    NT-0249 free base
  • HY-161305
    SE-7552

    		HDAC Metabolic Disease Cancer
    SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM. SE-7552 is greater than 850-fold selectivity versus all other known HDAC isozymes. SE-7552 is capable of blocking multiple myeloma growth in vivo. SE-7552 acts as an anti-obesity agent in diet-induced obese mice .
    SE-7552
  • HY-N14035
    Garcinia cambogia extract

    		FABP PPAR Metabolic Disease
    Garcinia cambogia extract is an orally active anti-obesity agent . Garcinia cambogia extract upregulates the gene expression of aP2, SREBP1c, PPARγ2 and C/EBPα. Garcinia cambogia extract reduces the rate of body weight gain, visceral fat accumulation, lipid levels in blood and liver, as well as plasma insulin and leptin levels . Garcinia cambogia extract ameliorates high-fat diet-induced obesity .
    Garcinia cambogia extract
  • HY-117912
    TRC210258

    		Endogenous Metabolite Cardiovascular Disease
    TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .
    TRC210258
  • HY-W012865
    Tartronic acid

    		Carnitine Palmitoyltransferase (CPT) Endogenous Metabolite FABP PPAR Metabolic Disease
    Tartronic acid, a dicarboxylic acid derive, is an inhibitor of the transformation of carbohydrates into fat under fat-deficient diet conditions. Tartronic acid promotes 3T3-L1 adipocyte differentiation by increasing the protein expression of FABP-4, PPARγ and SREBP-1. Tartronic acid promotes de novo lipogenesis and inhibits CPT-1β by upregulating acetyl-CoA and malonyl-CoA. Tartronic acid promotes weight gain and induces adipocyte hypertrophy in epididymal white adipose tissue and lipid accumulation in the livers of high-fat diet induced obese mice. Tartronic acid can be used for lipid metabolic disease research .
    Tartronic acid
  • HY-14811
    Beloranib

    ZGN-440; CKD-732 free base

    		 MetAP NF-κB Metabolic Disease
    Beloranib (ZGN-440; CKD-732 free base) is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib can be used in research on obesity and hypothalamic obesity .
    Beloranib
  • HY-128872
    Etrinabdione

    EHP-101; VCE-​004.8

    		 PPAR Cannabinoid Receptor HIF/HIF Prolyl-Hydroxylase Metabolic Disease Inflammation/Immunology
    Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity .
    Etrinabdione
  • HY-W587486R
    N-Acetyltaurine (Standard)

    		Reference Standards Endogenous Metabolite Bacterial Metabolic Disease
    N-Acetyltaurine (Standard) is the analytical standard of N-Acetyltaurine (HY-W587486). This product is intended for research and analytical applications. N‑acetyltaurine is an orally active endogenous sulfonate that is synthesized from taurine and acetate in the renal cortex. N‑acetyltaurine supports bacterial growth as a sole fixed nitrogen or carbon source. N‑acetyltaurine buffers acetyl moieties of mitochondrial acetyl‑CoA in skeletal muscle. N‑acetyltaurine reduces food intake and body weight in obese and lean wild‑type mice in a GFRAL‑dependent manner. N‑acetyltaurine can be used for the research of diet‑induced obesity, hyperacetatemia and diabetes .
    N-Acetyltaurine (Standard)
  • HY-14393R
    Emodin (Standard)
    Maximum Cited Publications
    39 Publications Verification

    Frangula emodin (Standard)

    		 Reference Standards SARS-CoV Casein Kinase Autophagy 11β-HSD Cancer
    Emodin (Standard) is the analytical standard of Emodin. This product is intended for research and analytical applications. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .
    Emodin (Standard)
  • HY-19325
    SKI2852

    		11β-HSD Metabolic Disease
    SKI2852 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC50s of 1.6 nM and 2.9 nM against mHSD1 and hHSD1, respectively .
    SKI2852
  • HY-157567
    FSI-TN42

    N42

    		 Aldehyde Dehydrogenase (ALDH) Metabolic Disease
    FSI-TN42 (N42) is a selective, orally active and irreversible ALDH1A1 inhibitor with an IC50 of 23 nM. FSI-TN42 shows 800-fold more potent against ALDH1A1 than ALDH1A2 (IC50diet induced mouse model of obesity .
    FSI-TN42
  • HY-161297
    NT-0249

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NT-0249 is an orally active NLRP3 inhibitor. NT-0249 has anti-inflammatory activity
    NT-0249
  • HY-151500A
    JBSNF-000028 TFA

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 TFA is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 TFA can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 TFA exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 TFA can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 TFA
  • HY-14811A
    Beloranib hemioxalate

    ZGN-440 hemioxalate; ZGN-433 hemioxalate; CDK732 hemioxalate

    		 NF-κB MetAP Metabolic Disease
    Beloranib (ZGN-440; CKD-732 free base) hemioxalate is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib hemioxalate blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib hemioxalate significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib hemioxalate also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib hemioxalate can be used in research on obesity and hypothalamic obesity .
    Beloranib hemioxalate
  • HY-151500C
    JBSNF-000028

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028
  • HY-N7394
    Galbacin

    (3S)-Zuonin A

    		 AMPK Metabolic Disease Cancer
    Galbacin ((3S)-Zuonin A), the epimer of (-)-Zuonin A (HY-N7394A), is a AMPK activator. Galbacin can be isolated from Myristica fragrans (nutmeg). Galbacin stimulates AMPK enzyme in differentiated C2C12 cells. Galbacin also has anticancer activity, and inhibits the proliferation of lymphocyte and tumor cells. Galbacin prevents weight gain in diet-induced mice model. Galbacin can be used for metabolic syndrome (including obesity and type-2 diabetes) and caners research .
    Galbacin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: